Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring
Health care professionals review considerations in transitioning breast cancer patients to the adjuvant setting and discuss response monitoring, treatment tailoring, and the evolving role of imaging.
EP: 1.Evolving HER2+ Breast Cancer Care: Neo-Adjuvant Strategies and Treatment Goals
EP: 2.Neoadjuvant Approaches in HER2+ Breast Cancer
EP: 3.HER2+ Breast Cancer: Anthracycline Considerations
EP: 4.Subcutaneous HER2+ Breast Cancer Treatment Trends
EP: 5.Adjuvant Strategies in HER2+ Brest Cancer: Timing and Tailoring
EP: 6.Evolving Strategies in Adjuvant HER2+ Breast Cancer
EP: 7.Exploring Therapeutic Avenues in HER2+ Breast Cancer
EP: 8.Metastatic HER2+ Breast Cancer: Current Strategies and Ongoing Trials
EP: 9.Navigating Second-Line Choices in HER2+ Breast Cancer
EP: 10.Decoding HER2+ Breast Cancer: Challenges in Brain Metastases
EP: 11.Navigating HER2+ Brain Metastases: Emerging Insights
EP: 12.HER2+ Breast Cancer Treatment Dynamics and Challenges
EP: 13.Navigating Treatment Challenges in HER2+ Breast Cancer
EP: 14.Insights and Challenges in Advancing HER2+ Breast Cancer Care
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy shifts the discussion to the adjuvant setting, prompting insights from Sharma on managing patients undergoing preoperative therapy. They explore the timing of surgeries and potential variations based on patient responses. Sharma emphasizes setting patient expectations for the entire regimen, often opting for imaging after 3 or 4 cycles to assess cancer response. The conversation touches on the role of reimaging and considerations for changing treatments based on imaging results, with a focus on MRI and PET scans.
Sharma discusses ongoing trials such as DIRECT, investigating PET scan results to guide preoperative therapy. Challenges related to obtaining PET coverage, especially for Medicaid patients, are acknowledged. The importance of tailoring therapy based on pathological response is highlighted, with specific considerations for T-DM1 (trastuzumab emtansine) post pathologic complete response. Sharma delves into biomarkers such as HER2 and immune signatures, indicating their potential in prognostic assessments.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
